Genetic Analysis of T-Cell Lymphomas Completed

Nick Mulcahy

August 06, 2012

August 6, 2012 — The first genome-wide analysis of peripheral T-cell lymphomas has been completed by American researchers.

A team from the Mayo Clinic in Rochester, Minnesota, found 13 genomic abnormalities that are common to peripheral T-cell lymphomas. Five of the genetic abnormalities are related to the p53 protein, which, when it is not mutated, plays a role in suppressing cancers.

The team's study was published online August 1 in the journal Blood.

"Every time I diagnose a peripheral T-cell lymphoma, I know that 2 out of 3 patients will succumb to that lymphoma," said lead author Andrew Feldman, MD, of the Center for Individualized Medicine at the Mayo Clinic, in a press statement. "That's a very unsatisfying feeling, and I hope that my research can help change those statistics."

Peripheral T-cell lymphomas are "aggressive" malignancies with 5-year overall survival rates of about 35%, according to Dr. Feldman and his coauthors.

"Improvement in outcomes has been stymied by poor understanding of the genetics and molecular pathogenesis of peripheral T-cell lymphoma, with a resulting paucity of molecular targets for therapy," they write.

The researchers hope the new genetic information will be used to improve diagnostic tests and develop targeted treatments for peripheral T-cell lymphoma.

Currently, the field of hematologic oncology is somewhat in the dark when diagnosing and treating these lymphomas, suggested Dr. Feldman.

"The most common type of T-cell lymphoma is called 'not otherwise specified' — it's basically a wastebasket diagnosis because we don't understand enough about the specific genetic abnormalities to be able to pinpoint specific subtypes of T-cell lymphomas that might trigger different treatments by the treating oncologist," said Dr. Feldman.

To address the problem, the team developed bioinformatic tools to identify chromosomal rearrangements using genome-wide, next-generation sequencing analysis of DNA libraries. The tools were used to analyze 16 peripheral T-cell lymphoma patient tissue samples and 6 related cell lines.

Of the 5 p53-related genes identified, one abnormality was most common, that of TP63.

TP63 rearrangements were seen in 11/190 (5.8%) of peripheral T-cell lymphoma and were associated with inferior overall survival.

The researchers also highlighted the finding of TP53 mutations but acknowledged that they are "rare" in peripheral T-cell lymphoma compared with other malignancies. "Our findings suggest that a constellation of alternate genetic abnormalities may contribute to disruption of p53-associated tumor suppressor function in PTCL," they write.

The study was supported by a grant from Bernard and Edith Waterman.

Blood. Published online August 1, 2012. Abstract


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.